Manufacturing News of Note—AveXis goes deeper on Zolgensma manufacturing; 76B opioid pills manufactured

stocks
According to a new report, the active pharmaceutical ingredient market is projected to reach $213.84 billion in 2021, up from $148.22 billion in 2015. (Pixabay)

Here is some news of note for the week: 

> Catalent Biologics and Novartis’ company AveXis have struck a long-term deal in which the biotech will have dedicated manufacturing space at a Catalent facility for the production of AveXis' Zolgensma, its newly approved gene therapy for spinal muscular atrophy. Release 

> Data recently released as part of a civil action show that U.S. drugmakers manufactured 76 billion oxycodone and hydrocodone pills from 2006 through 2012 as the opioid epidemic spread. Story

> According to a new report, the active pharmaceutical ingredient market is projected to reach $213.84 billion in 2021, up from $148.22 billion in 2015. Release

 


 

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

CureVac has tapped Wacker to help produce 100 million doses of its mRNA-based COVID-19 vaccine at its Amsterdam facility.